You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAtomoxetine
Accession NumberDB00289  (APRD00614)
TypeSmall Molecule
GroupsApproved
DescriptionAtomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]
Structure
Thumb
Synonyms
(-)-Tomoxetine
Tomoxetina
Tomoxetine
Tomoxetinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atomoxetinecapsule18 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule10 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule60 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule25 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule18 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule40 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule25 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule10 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule60 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule40 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Dom-atomoxetinecapsule18 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-atomoxetinecapsule25 mgoralDominion Pharmacal2013-04-23Not applicableCanada
Dom-atomoxetinecapsule40 mgoralDominion Pharmacal2013-04-23Not applicableCanada
Dom-atomoxetinecapsule10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-atomoxetinecapsule60 mgoralDominion Pharmacal2013-05-22Not applicableCanada
Mylan-atomoxetinecapsule40 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule60 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule18 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule80 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule25 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule100 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
PMS-atomoxetinecapsule10 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule60 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule18 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule80 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-atomoxetinecapsule25 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule100 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-atomoxetinecapsule40 mgoralPharmascience Inc2012-06-13Not applicableCanada
Ratio-atomoxetinecapsule40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule60 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule18 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Riva-atomoxetinecapsule25 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule100 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-atomoxetinecapsule40 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule10 mgoralLaboratoire Riva Inc2013-07-18Not applicableCanada
Riva-atomoxetinecapsule60 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule18 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule80 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz Atomoxetinecapsule25 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule100 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule40 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule10 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule60 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule18 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule80 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
StratterakitoralEli Lilly and Company2014-08-31Not applicableUs
Stratteracapsule10 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Stratteracapsule10 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule40 mg/1oralCardinal Health2003-01-10Not applicableUs
Stratteracapsule80 mgoralEli Lilly Canada Inc2009-12-16Not applicableCanada
Stratteracapsule40 mg/1oralREMEDYREPACK INC.2013-05-09Not applicableUs
Stratteracapsule18 mgoralEli Lilly Canada Inc2005-02-24Not applicableCanada
Stratteracapsule60 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule25 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
StratterakitoralEli Lilly and Company2014-08-31Not applicableUs
Stratteracapsule25 mg/1oralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Stratteracapsule25 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule25 mg/1oralTYA Pharmaceuticals2003-01-10Not applicableUs
Stratteracapsule100 mgoralEli Lilly Canada Inc2010-01-08Not applicableCanada
Stratteracapsule18 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-13Not applicableUs
Stratteracapsule25 mgoralEli Lilly Canada Inc2005-03-03Not applicableCanada
Stratteracapsule40 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Stratteracapsule80 mg/1oralEli Lilly and Company2006-03-01Not applicableUs
StratterakitoralEli Lilly and Company2014-08-31Not applicableUs
Stratteracapsule40 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Stratteracapsule40 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule10 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Stratteracapsule40 mgoralEli Lilly Canada Inc2005-03-03Not applicableCanada
Stratteracapsule80 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Stratteracapsule100 mg/1oralEli Lilly and Company2006-03-01Not applicableUs
Stratteracapsule60 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Stratteracapsule10 mg/1oralSTAT Rx USA LLC2009-03-16Not applicableUs
Stratteracapsule10 mgoralEli Lilly Canada Inc2005-02-24Not applicableCanada
Stratteracapsule18 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule18 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Stratteracapsule25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-13Not applicableUs
Stratteracapsule60 mgoralEli Lilly Canada Inc2005-03-03Not applicableCanada
Teva-atomoxetinecapsule80 mgoralTeva Canada Limited2014-02-28Not applicableCanada
Teva-atomoxetinecapsule25 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule100 mgoralTeva Canada Limited2013-10-15Not applicableCanada
Teva-atomoxetinecapsule40 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule10 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule60 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule18 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atomoxetinecapsule18 mgoralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetinecapsule80 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule25 mgoralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetinecapsule100 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule40 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule60 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule10 mgoralApotex Inc2011-03-15Not applicableCanada
Atomoxetine Hydrochloridecapsule10 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule10 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule60 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule60 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule18 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule18 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule80 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule80 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule25 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule25 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule100 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule100 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule40 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule40 mg/1oralSandoz Inc2010-12-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AttentinNot Available
TomoxetinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Atomoxetine hydrochloride
82248-59-7
Thumb
  • InChI Key: LUCXVPAZUDVVBT-UNTBIKODSA-N
  • Monoisotopic Mass: 291.138992
  • Average Mass: 291.82
DBSALT001207
Categories
UNIIASW034S0B8
CAS number83015-26-3
WeightAverage: 255.3547
Monoisotopic: 255.162314299
Chemical FormulaC17H21NO
InChI KeyInChIKey=VHGCDTVCOLNTBX-QGZVFWFLSA-N
InChI
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
IUPAC Name
methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine
SMILES
CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenol ether
  • Aralkylamine
  • Toluene
  • Alkyl aryl ether
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.
PharmacodynamicsAtomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.
Mechanism of actionThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.
Related Articles
AbsorptionAtomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food.
Volume of distribution
  • 0.85 L/kg
Protein bindingAt therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin.
Metabolism

Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs).

SubstrateEnzymesProduct
Atomoxetine
Not Available
4-hydroxyatomoxetineDetails
Route of eliminationNot Available
Half life5 hours
Clearance
  • 0.35 L/hr/kg [after oral administration in adult extensive metabolizers]
  • 0.03 L/hr/kg [administration of atomoxetine to poor metabolizers]
ToxicityThe most commonly reported symptoms accompanying acute and chronic overdoses are somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.964
Caco-2 permeable+0.852
P-glycoprotein substrateSubstrate0.6133
P-glycoprotein inhibitor IInhibitor0.7771
P-glycoprotein inhibitor IINon-inhibitor0.8003
Renal organic cation transporterInhibitor0.5929
CYP450 2C9 substrateNon-substrate0.7443
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6216
CYP450 1A2 substrateInhibitor0.9324
CYP450 2C9 inhibitorNon-inhibitor0.957
CYP450 2D6 inhibitorInhibitor0.9037
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8122
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7371
Ames testNon AMES toxic0.7738
CarcinogenicityNon-carcinogens0.8493
BiodegradationNot ready biodegradable0.8013
Rat acute toxicity2.5166 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7132
hERG inhibition (predictor II)Inhibitor0.7974
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg/1
Capsuleoral10 mg
Capsuleoral100 mg
Capsuleoral100 mg/1
Capsuleoral18 mg/1
Capsuleoral18 mg
Capsuleoral25 mg
Capsuleoral25 mg/1
Capsuleoral40 mg/1
Capsuleoral40 mg
Capsuleoral60 mg
Capsuleoral60 mg/1
Capsuleoral80 mg
Capsuleoral80 mg/1
Kitoral
Prices
Unit descriptionCostUnit
Strattera 80 mg capsule6.94USD capsule
Strattera 100 mg capsule6.83USD capsule
Strattera 40 mg capsule6.43USD capsule
Strattera 60 mg capsule6.43USD capsule
Strattera 18 mg capsule6.03USD capsule
Strattera 25 mg capsule5.85USD capsule
Strattera 10 mg capsule5.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2209735 No2002-10-012016-01-04Canada
US5658590 Yes1997-05-262017-05-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility27.8 mg/mLNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0039 mg/mLALOGPS
logP3.95ALOGPS
logP3.81ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity79.44 m3·mol-1ChemAxon
Polarizability29.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei, “Processes for the preparation of atomoxetine hydrochloride.” U.S. Patent US20060211772, issued September 21, 2006.

US20060211772
General References
  1. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. [PubMed:16649828 ]
  2. Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. [PubMed:16555170 ]
  3. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. [PubMed:16259536 ]
  4. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. [PubMed:16113620 ]
  5. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. [PubMed:17388708 ]
  6. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  7. Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-22. [PubMed:14717619 ]
  8. Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. [PubMed:19785510 ]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
External Links
ATC CodesN06BA09
AHFS Codes
  • 28:92.00
PDB EntriesNot Available
FDA labelDownload (72.8 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Atomoxetine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the central neurotoxic activities of Atomoxetine.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Atomoxetine.
AcebutololAtomoxetine may increase the hypertensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Atomoxetine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Atomoxetine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Atomoxetine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Atomoxetine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Atomoxetine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Atomoxetine.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Atomoxetine.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Atomoxetine.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Atomoxetine.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Atomoxetine.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Atomoxetine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Atomoxetine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Atomoxetine.
AlosetronThe metabolism of Alosetron can be decreased when combined with Atomoxetine.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Atomoxetine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Atomoxetine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Atomoxetine.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Atomoxetine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Atomoxetine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Atomoxetine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Atomoxetine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Atomoxetine.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Atomoxetine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Atomoxetine.
AmphetamineAtomoxetine may increase the hypertensive activities of Amphetamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Atomoxetine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Atomoxetine.
AnagrelideAtomoxetine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Atomoxetine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Atomoxetine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Atomoxetine.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Atomoxetine.
AprindineThe metabolism of Aprindine can be decreased when combined with Atomoxetine.
ArbutamineAtomoxetine may increase the tachycardic activities of Arbutamine.
ArformoterolAtomoxetine may increase the tachycardic activities of Arformoterol.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Atomoxetine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.
ArmodafinilThe metabolism of Atomoxetine can be decreased when combined with Armodafinil.
Arsenic trioxideAtomoxetine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Artemether can be decreased when combined with Atomoxetine.
AsenapineThe metabolism of Asenapine can be decreased when combined with Atomoxetine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Atomoxetine.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Atomoxetine.
AvanafilThe metabolism of Avanafil can be decreased when combined with Atomoxetine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Atomoxetine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Atomoxetine.
AzithromycinAtomoxetine may increase the QTc-prolonging activities of Azithromycin.
BambuterolAtomoxetine may increase the tachycardic activities of Bambuterol.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Atomoxetine.
BedaquilineAtomoxetine may increase the QTc-prolonging activities of Bedaquiline.
BenmoxinBenmoxin may increase the central neurotoxic activities of Atomoxetine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Atomoxetine.
BenzphetamineAtomoxetine may increase the hypertensive activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Atomoxetine.
BepridilThe metabolism of Bepridil can be decreased when combined with Atomoxetine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Atomoxetine.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Atomoxetine.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Atomoxetine.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Atomoxetine.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Atomoxetine.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Atomoxetine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Atomoxetine.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Atomoxetine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atomoxetine.
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Atomoxetine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Atomoxetine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Atomoxetine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Atomoxetine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Atomoxetine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Atomoxetine.
BudesonideThe metabolism of Budesonide can be decreased when combined with Atomoxetine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Atomoxetine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Atomoxetine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Atomoxetine.
BupropionThe serum concentration of Atomoxetine can be increased when it is combined with Bupropion.
BupropionThe metabolism of Bupropion can be decreased when combined with Atomoxetine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Atomoxetine.
BusulfanThe metabolism of Busulfan can be decreased when combined with Atomoxetine.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Atomoxetine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Atomoxetine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Atomoxetine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Atomoxetine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Atomoxetine.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Atomoxetine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Atomoxetine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Atomoxetine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Atomoxetine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Atomoxetine.
CaroxazoneCaroxazone may increase the central neurotoxic activities of Atomoxetine.
CarteololThe metabolism of Carteolol can be decreased when combined with Atomoxetine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Atomoxetine.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Atomoxetine.
CeliprololAtomoxetine may increase the hypertensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Atomoxetine.
CeritinibAtomoxetine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Atomoxetine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Atomoxetine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Atomoxetine.
ChloramphenicolThe metabolism of Atomoxetine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Atomoxetine.
ChloroquineAtomoxetine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Atomoxetine can be decreased when combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Atomoxetine.
ChlorphentermineAtomoxetine may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineAtomoxetine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Atomoxetine can be decreased when combined with Chlorpromazine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Atomoxetine.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Atomoxetine.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Atomoxetine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Atomoxetine.
CimetidineThe metabolism of Atomoxetine can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Atomoxetine can be increased when it is combined with Cinacalcet.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Atomoxetine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Atomoxetine.
CiprofloxacinAtomoxetine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Atomoxetine.
CitalopramThe metabolism of Citalopram can be decreased when combined with Atomoxetine.
ClarithromycinAtomoxetine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Atomoxetine can be decreased when combined with Clemastine.
ClenbuterolAtomoxetine may increase the hypertensive activities of Clenbuterol.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Atomoxetine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Atomoxetine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Atomoxetine.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Atomoxetine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Atomoxetine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Atomoxetine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Atomoxetine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Atomoxetine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Atomoxetine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Atomoxetine.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Atomoxetine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Atomoxetine.
ClotrimazoleThe metabolism of Atomoxetine can be decreased when combined with Clotrimazole.
ClozapineAtomoxetine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Atomoxetine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Atomoxetine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atomoxetine.
CocaineThe serum concentration of Atomoxetine can be increased when it is combined with Cocaine.
CocaineThe metabolism of Cocaine can be decreased when combined with Atomoxetine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Atomoxetine.
ColchicineThe metabolism of Colchicine can be decreased when combined with Atomoxetine.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Atomoxetine.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Atomoxetine.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Atomoxetine.
CrizotinibAtomoxetine may increase the QTc-prolonging activities of Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Atomoxetine.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Atomoxetine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Atomoxetine.
DabrafenibThe serum concentration of Atomoxetine can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Atomoxetine.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Atomoxetine.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Atomoxetine.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Atomoxetine.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atomoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Atomoxetine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Atomoxetine.
DarunavirThe serum concentration of Atomoxetine can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Atomoxetine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Atomoxetine.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Atomoxetine.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Atomoxetine.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Atomoxetine.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Atomoxetine.
DelavirdineThe serum concentration of Atomoxetine can be increased when it is combined with Delavirdine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Atomoxetine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Atomoxetine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Atomoxetine.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Atomoxetine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Atomoxetine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Atomoxetine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Atomoxetine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Atomoxetine.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Atomoxetine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Atomoxetine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Atomoxetine.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Atomoxetine.
DigoxinThe metabolism of Digoxin can be decreased when combined with Atomoxetine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Atomoxetine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Atomoxetine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Atomoxetine.
DipivefrinAtomoxetine may increase the tachycardic activities of Dipivefrin.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Atomoxetine.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Atomoxetine.
DobutamineAtomoxetine may increase the hypertensive activities of Dobutamine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Atomoxetine.
DolasetronAtomoxetine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atomoxetine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Atomoxetine.
DopamineAtomoxetine may increase the hypertensive activities of Dopamine.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Atomoxetine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Atomoxetine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Atomoxetine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Atomoxetine.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Atomoxetine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Atomoxetine.
DroperidolAtomoxetine may increase the QTc-prolonging activities of Droperidol.
DroxidopaAtomoxetine may increase the tachycardic activities of Droxidopa.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Atomoxetine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Atomoxetine.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Atomoxetine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Atomoxetine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Atomoxetine.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Atomoxetine.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Atomoxetine.
EncainideThe metabolism of Encainide can be decreased when combined with Atomoxetine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Atomoxetine.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Atomoxetine.
EphedraAtomoxetine may increase the tachycardic activities of Ephedra.
EphedrineAtomoxetine may increase the hypertensive activities of Ephedrine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Atomoxetine.
EpinephrineAtomoxetine may increase the hypertensive activities of Epinephrine.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Atomoxetine.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Atomoxetine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Atomoxetine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Atomoxetine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Atomoxetine.
ErythromycinAtomoxetine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Atomoxetine.
Eslicarbazepine acetateThe metabolism of Atomoxetine can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Atomoxetine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Atomoxetine.
EstazolamThe metabolism of Estazolam can be decreased when combined with Atomoxetine.
EstradiolThe metabolism of Estradiol can be decreased when combined with Atomoxetine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Atomoxetine.
EstramustineThe metabolism of Estramustine can be decreased when combined with Atomoxetine.
EstroneThe metabolism of Estrone can be decreased when combined with Atomoxetine.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Atomoxetine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Atomoxetine.
EthanolThe metabolism of Ethanol can be decreased when combined with Atomoxetine.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Atomoxetine.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Atomoxetine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Atomoxetine.
EtilefrineAtomoxetine may increase the hypertensive activities of Etilefrine.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Atomoxetine.
EtoposideThe metabolism of Etoposide can be decreased when combined with Atomoxetine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Atomoxetine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Atomoxetine.
EverolimusThe metabolism of Everolimus can be decreased when combined with Atomoxetine.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Atomoxetine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Atomoxetine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Atomoxetine.
FelodipineThe metabolism of Felodipine can be decreased when combined with Atomoxetine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Atomoxetine.
FenoterolAtomoxetine may increase the hypertensive activities of Fenoterol.
FentanylThe metabolism of Fentanyl can be decreased when combined with Atomoxetine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Atomoxetine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Atomoxetine.
FlecainideAtomoxetine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Atomoxetine.
FluconazoleThe metabolism of Atomoxetine can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Atomoxetine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Atomoxetine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Atomoxetine.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Atomoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Atomoxetine.
FlupentixolAtomoxetine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Atomoxetine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Atomoxetine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Atomoxetine.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Atomoxetine.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Atomoxetine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Atomoxetine.
FluvoxamineThe metabolism of Atomoxetine can be decreased when combined with Fluvoxamine.
FormoterolAtomoxetine may increase the tachycardic activities of Formoterol.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Atomoxetine.
FosphenytoinThe metabolism of Atomoxetine can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Atomoxetine.
FurazolidoneFurazolidone may increase the central neurotoxic activities of Atomoxetine.
Gadobenic acidAtomoxetine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Atomoxetine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Atomoxetine.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Atomoxetine.
GemifloxacinAtomoxetine may increase the QTc-prolonging activities of Gemifloxacin.
GlipizideThe metabolism of Glipizide can be decreased when combined with Atomoxetine.
GlyburideThe metabolism of Glyburide can be decreased when combined with Atomoxetine.
GoserelinAtomoxetine may increase the QTc-prolonging activities of Goserelin.
GranisetronAtomoxetine may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Atomoxetine.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Atomoxetine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Atomoxetine.
HaloperidolAtomoxetine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Atomoxetine can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Atomoxetine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Atomoxetine.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Atomoxetine.
HydracarbazineHydracarbazine may increase the central neurotoxic activities of Atomoxetine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Atomoxetine.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Atomoxetine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Atomoxetine.
Hydroxyamphetamine hydrobromideAtomoxetine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Atomoxetine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Atomoxetine.
IbutilideAtomoxetine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Atomoxetine.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atomoxetine resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Atomoxetine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Atomoxetine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Atomoxetine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Atomoxetine.
IndacaterolAtomoxetine may increase the tachycardic activities of Indacaterol.
IndapamideThe metabolism of Indapamide can be decreased when combined with Atomoxetine.
IndinavirThe metabolism of Indinavir can be decreased when combined with Atomoxetine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Atomoxetine.
IproclozideIproclozide may increase the central neurotoxic activities of Atomoxetine.
IproniazidIproniazid may increase the central neurotoxic activities of Atomoxetine.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Atomoxetine.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Atomoxetine.
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.
IsoetarineAtomoxetine may increase the tachycardic activities of Isoetarine.
IsoniazidThe metabolism of Atomoxetine can be decreased when combined with Isoniazid.
IsoprenalineAtomoxetine may increase the hypertensive activities of Isoprenaline.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atomoxetine.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atomoxetine.
IsoxsuprineAtomoxetine may increase the hypertensive activities of Isoxsuprine.
IsradipineThe metabolism of Isradipine can be decreased when combined with Atomoxetine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Atomoxetine.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Atomoxetine.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Atomoxetine.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Atomoxetine.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Atomoxetine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Atomoxetine.
KetamineThe metabolism of Ketamine can be decreased when combined with Atomoxetine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Atomoxetine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Atomoxetine.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Atomoxetine.
LabetalolAtomoxetine may increase the hypertensive activities of Labetalol.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Atomoxetine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Atomoxetine.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Atomoxetine.
LenvatinibAtomoxetine may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Atomoxetine.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Atomoxetine.
LeuprolideAtomoxetine may increase the QTc-prolonging activities of Leuprolide.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Atomoxetine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Atomoxetine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Atomoxetine.
LevofloxacinAtomoxetine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Atomoxetine.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Atomoxetine.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Atomoxetine.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Atomoxetine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Atomoxetine.
LisurideThe metabolism of Lisuride can be decreased when combined with Atomoxetine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Atomoxetine.
LomustineThe metabolism of Lomustine can be decreased when combined with Atomoxetine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Atomoxetine.
LopinavirThe serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Atomoxetine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Atomoxetine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Atomoxetine.
LosartanThe metabolism of Losartan can be decreased when combined with Atomoxetine.
LovastatinThe metabolism of Lovastatin can be decreased when combined with Atomoxetine.
LuliconazoleThe serum concentration of Atomoxetine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Atomoxetine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Atomoxetine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Atomoxetine.
MacitentanThe metabolism of Macitentan can be decreased when combined with Atomoxetine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Atomoxetine.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Atomoxetine.
MebanazineMebanazine may increase the central neurotoxic activities of Atomoxetine.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Atomoxetine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Atomoxetine.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Atomoxetine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Atomoxetine.
MephentermineAtomoxetine may increase the hypertensive activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Atomoxetine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Atomoxetine.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Atomoxetine.
MetaraminolAtomoxetine may increase the hypertensive activities of Metaraminol.
MethadoneAtomoxetine may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Atomoxetine can be decreased when combined with Methadone.
MethamphetamineAtomoxetine may increase the hypertensive activities of Methamphetamine.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Atomoxetine.
MethotrimeprazineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Atomoxetine.
MethoxamineAtomoxetine may increase the hypertensive activities of Methoxamine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Atomoxetine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Atomoxetine.
Methylene blueMethylene blue may increase the central neurotoxic activities of Atomoxetine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Atomoxetine.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Atomoxetine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Atomoxetine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Atomoxetine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Atomoxetine.
MetoprololThe metabolism of Atomoxetine can be decreased when combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Atomoxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Atomoxetine.
MianserinThe metabolism of Mianserin can be decreased when combined with Atomoxetine.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Atomoxetine.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Atomoxetine.
MidazolamThe metabolism of Midazolam can be decreased when combined with Atomoxetine.
MidodrineAtomoxetine may increase the hypertensive activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Atomoxetine.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Atomoxetine.
MinaprineMinaprine may increase the central neurotoxic activities of Atomoxetine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Atomoxetine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Atomoxetine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Atomoxetine.
MoclobemideMoclobemide may increase the central neurotoxic activities of Atomoxetine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Atomoxetine.
ModafinilThe metabolism of Modafinil can be decreased when combined with Atomoxetine.
MontelukastThe metabolism of Montelukast can be decreased when combined with Atomoxetine.
MorphineThe metabolism of Morphine can be decreased when combined with Atomoxetine.
MoxifloxacinAtomoxetine may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Atomoxetine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atomoxetine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Atomoxetine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Atomoxetine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Atomoxetine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Atomoxetine.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Atomoxetine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Atomoxetine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Atomoxetine.
NialamideNialamide may increase the central neurotoxic activities of Atomoxetine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Atomoxetine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Atomoxetine.
NicotineThe metabolism of Nicotine can be decreased when combined with Atomoxetine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Atomoxetine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Atomoxetine.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Atomoxetine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Atomoxetine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atomoxetine.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Atomoxetine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Atomoxetine.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Atomoxetine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Atomoxetine.
NorepinephrineAtomoxetine may increase the hypertensive activities of Norepinephrine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Atomoxetine.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Atomoxetine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Atomoxetine.
NylidrinAtomoxetine may increase the hypertensive activities of Nylidrin.
OctamoxinOctamoxin may increase the central neurotoxic activities of Atomoxetine.
OfloxacinAtomoxetine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Atomoxetine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Atomoxetine.
OlodaterolAtomoxetine may increase the tachycardic activities of Olodaterol.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Atomoxetine.
OndansetronAtomoxetine may increase the QTc-prolonging activities of Ondansetron.
OrciprenalineAtomoxetine may increase the hypertensive activities of Orciprenaline.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Atomoxetine.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Atomoxetine.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Atomoxetine.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Atomoxetine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Atomoxetine.
OxymetazolineAtomoxetine may increase the hypertensive activities of Oxymetazoline.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Atomoxetine.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Atomoxetine.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Atomoxetine.
PaliperidoneAtomoxetine may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Atomoxetine.
PanobinostatAtomoxetine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Atomoxetine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Atomoxetine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Atomoxetine.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Atomoxetine.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Atomoxetine.
PargylinePargyline may increase the central neurotoxic activities of Atomoxetine.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Atomoxetine.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Atomoxetine.
ParoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Atomoxetine.
PazopanibAtomoxetine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineAtomoxetine may increase the QTc-prolonging activities of Pentamidine.
PerampanelThe metabolism of Perampanel can be decreased when combined with Atomoxetine.
PerflutrenAtomoxetine may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Atomoxetine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Atomoxetine.
PermethrinThe metabolism of Permethrin can be decreased when combined with Atomoxetine.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Atomoxetine.
PethidineThe metabolism of Pethidine can be decreased when combined with Atomoxetine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Atomoxetine.
PhenelzinePhenelzine may increase the central neurotoxic activities of Atomoxetine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Atomoxetine.
PheniprazinePheniprazine may increase the central neurotoxic activities of Atomoxetine.
PhenmetrazineAtomoxetine may increase the hypertensive activities of Phenmetrazine.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Atomoxetine.
PhenoxypropazinePhenoxypropazine may increase the central neurotoxic activities of Atomoxetine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Atomoxetine.
PhentermineAtomoxetine may increase the hypertensive activities of Phentermine.
PhenylephrineAtomoxetine may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineAtomoxetine may increase the hypertensive activities of Phenylpropanolamine.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Atomoxetine.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Atomoxetine.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Atomoxetine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Atomoxetine.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Atomoxetine.
PindololThe metabolism of Pindolol can be decreased when combined with Atomoxetine.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Atomoxetine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Atomoxetine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Atomoxetine.
PirbuterolAtomoxetine may increase the tachycardic activities of Pirbuterol.
PirlindolePirlindole may increase the central neurotoxic activities of Atomoxetine.
PivhydrazinePivhydrazine may increase the central neurotoxic activities of Atomoxetine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Atomoxetine.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Atomoxetine.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Atomoxetine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Atomoxetine.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Atomoxetine.
PrazepamThe metabolism of Prazepam can be decreased when combined with Atomoxetine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Atomoxetine.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Atomoxetine.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Atomoxetine.
PrimaquineAtomoxetine may increase the QTc-prolonging activities of Primaquine.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Atomoxetine.
ProcaterolAtomoxetine may increase the hypertensive activities of Procaterol.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Atomoxetine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Atomoxetine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Atomoxetine.
PromazineAtomoxetine may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Atomoxetine can be decreased when combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Atomoxetine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Atomoxetine.
PropofolThe metabolism of Propofol can be decreased when combined with Atomoxetine.
PropranololThe metabolism of Propranolol can be decreased when combined with Atomoxetine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Atomoxetine.
PseudoephedrineAtomoxetine may increase the hypertensive activities of Pseudoephedrine.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Atomoxetine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Atomoxetine.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Atomoxetine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Atomoxetine.
QuinidineThe serum concentration of Atomoxetine can be increased when it is combined with Quinidine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Atomoxetine.
QuinineThe metabolism of Quinine can be decreased when combined with Atomoxetine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Atomoxetine.
RacepinephrineAtomoxetine may increase the hypertensive activities of Racepinephrine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Atomoxetine.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Atomoxetine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Atomoxetine.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Atomoxetine.
RasagilineRasagiline may increase the central neurotoxic activities of Atomoxetine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Atomoxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Atomoxetine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Atomoxetine.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Atomoxetine.
repinotanThe metabolism of repinotan can be decreased when combined with Atomoxetine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Atomoxetine.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Atomoxetine.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Atomoxetine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Atomoxetine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Atomoxetine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Atomoxetine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Atomoxetine.
RitodrineAtomoxetine may increase the hypertensive activities of Ritodrine.
RitonavirThe serum concentration of Atomoxetine can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Atomoxetine.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Atomoxetine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Atomoxetine.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Atomoxetine.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Atomoxetine.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Atomoxetine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Atomoxetine.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Atomoxetine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Atomoxetine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Atomoxetine.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Atomoxetine.
SafrazineSafrazine may increase the central neurotoxic activities of Atomoxetine.
SalbutamolAtomoxetine may increase the tachycardic activities of Salbutamol.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Atomoxetine.
SaquinavirAtomoxetine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Atomoxetine.
SelegilineSelegiline may increase the central neurotoxic activities of Atomoxetine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Atomoxetine.
SelexipagThe metabolism of Selexipag can be decreased when combined with Atomoxetine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Atomoxetine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Atomoxetine.
SertralineThe metabolism of Sertraline can be decreased when combined with Atomoxetine.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Atomoxetine.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Atomoxetine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Atomoxetine.
SilodosinThe metabolism of Silodosin can be decreased when combined with Atomoxetine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Atomoxetine.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Atomoxetine.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Atomoxetine.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Atomoxetine.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Atomoxetine.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Atomoxetine.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Atomoxetine.
SotalolAtomoxetine may increase the QTc-prolonging activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Atomoxetine.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Atomoxetine.
StiripentolThe serum concentration of Atomoxetine can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Atomoxetine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Atomoxetine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Atomoxetine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Atomoxetine.
SulfisoxazoleAtomoxetine may increase the QTc-prolonging activities of Sulfisoxazole.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Atomoxetine.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Atomoxetine.
SynephrineAtomoxetine may increase the hypertensive activities of Synephrine.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Atomoxetine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atomoxetine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Atomoxetine.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Atomoxetine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Atomoxetine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Atomoxetine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Atomoxetine.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Atomoxetine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Atomoxetine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Atomoxetine.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Atomoxetine.
TelavancinAtomoxetine may increase the QTc-prolonging activities of Telavancin.
TelithromycinAtomoxetine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Atomoxetine.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Atomoxetine.
TerbinafineThe serum concentration of Atomoxetine can be increased when it is combined with Terbinafine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Atomoxetine.
TerbutalineAtomoxetine may increase the hypertensive activities of Terbutaline.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Atomoxetine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Atomoxetine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Atomoxetine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Atomoxetine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Atomoxetine.
TetryzolineAtomoxetine may increase the hypertensive activities of Tetryzoline.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Atomoxetine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Atomoxetine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Atomoxetine.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Atomoxetine.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Atomoxetine.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Atomoxetine.
TimololThe metabolism of Timolol can be decreased when combined with Atomoxetine.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Atomoxetine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Atomoxetine.
TipranavirThe serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Atomoxetine.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Atomoxetine.
ToloxatoneToloxatone may increase the central neurotoxic activities of Atomoxetine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Atomoxetine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atomoxetine.
TopiramateThe metabolism of Atomoxetine can be decreased when combined with Topiramate.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Atomoxetine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Atomoxetine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Atomoxetine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central neurotoxic activities of Atomoxetine.
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Atomoxetine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Atomoxetine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Atomoxetine.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Atomoxetine.
TriazolamThe metabolism of Triazolam can be decreased when combined with Atomoxetine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Atomoxetine.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Atomoxetine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Atomoxetine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Atomoxetine.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Atomoxetine.
TyramineAtomoxetine may increase the hypertensive activities of Tyramine.
UdenafilThe metabolism of Udenafil can be decreased when combined with Atomoxetine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atomoxetine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Atomoxetine.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Atomoxetine.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Atomoxetine.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Atomoxetine.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Atomoxetine.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Atomoxetine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Atomoxetine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Atomoxetine.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Atomoxetine.
VilanterolAtomoxetine may increase the tachycardic activities of Vilanterol.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Atomoxetine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Atomoxetine.
VincristineThe metabolism of Vincristine can be decreased when combined with Atomoxetine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Atomoxetine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Atomoxetine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Atomoxetine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Atomoxetine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Atomoxetine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Atomoxetine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Atomoxetine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Atomoxetine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Atomoxetine.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Atomoxetine.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Atomoxetine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Atomoxetine.
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Atomoxetine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Atomoxetine.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Atomoxetine.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Atomoxetine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Atomoxetine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Atomoxetine.
Food Interactions
  • In the presence of food, the absorption rate is reduced, without the quantity absorbed being affected.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75. [PubMed:12456942 ]
  2. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. [PubMed:12523874 ]
  3. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 Jan 15;53(2):112-20. [PubMed:12547466 ]
  4. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. [PubMed:12862507 ]
  5. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5. [PubMed:14709944 ]
  6. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
  7. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004 Oct;8(2):45-52. [PubMed:15801334 ]
  8. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
  10. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [PubMed:12431845 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Fohr KJ: Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010 May;160(2):283-91. doi: 10.1111/j.1476-5381.2010.00707.x. [PubMed:20423340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  2. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:31